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Abstract
Background: Increased reactive oxygen species and estrogen deficiency contribute to the pathophysiology of
postmenopausal osteoporosis. Reactive oxygen species contribute to bone degradation and is necessary for RANKL-
induced osteoclast differentiation. In postmenopausal bone loss, reactive oxygen species can also activate immune
cells to further enhance bone resorption. Here, we investigated the role of reactive oxygen species in ovariectomy-
induced osteoporosis in mice deficient in Ncf1, a subunit for the NADPH oxidase 2 and a well-known regulator of
the immune system.
Methods: B10.Q wild-type (WT) mice and mice with a spontaneous point mutation in the Ncf1-gene (Ncf1*/*) were
ovariectomized (ovx) or sham-operated. After 4 weeks, osteoclasts were generated ex vivo, and bone mineral
density was measured using peripheral quantitative computed tomography. Lymphocyte populations,
macrophages, pre-osteoclasts and intracellular reactive oxygen species were analyzed by flow cytometry.
Results: After ovx, Ncf1*/*-mice formed fewer osteoclasts ex vivo compared to WT mice. However, trabecular bone
mineral density decreased similarly in both genotypes after ovx. Ncf1*/*-mice had a larger population of pre-
osteoclasts, whereas lymphocytes were activated to the same extent in both genotypes.
Conclusion: Ncf1*/*-mice develop fewer osteoclasts after ovx than WT mice. However, irrespective of genotype,
bone mineral density decreases after ovx, indicating that a compensatory mechanism retains bone degradation
after ovx.
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Background
Bone remodeling occurs throughout life, shifting to favor
bone resorption in postmenopausal women. Osteoclasts
(OCL) resorb bone, and the presence of reactive oxygen
species (ROS) at the interface between OCL and bone
suggests a role for ROS in bone resorption [1–4]. ROS are
produced by membrane-localized nicotinamide adenine
dinucleotide phosphate (NADPH) oxidases (NOX); [5],
where NOX 1, 2, and 4 are active in OCL and their mye-
loid precursor cells [1, 4]. The activity of NOX 2 is regu-
lated by the neutrophil cytosolic factor 1 (Ncf1, alias
p47phox) subunit [6]. ROS from NOX 2 kills bacteria in
professional phagocytes (such as macrophages and
neutrophils with highly efficient phagocytosis), and dam-
ages cells and tissues during inflammation. However, re-
duced production of ROS in mice lacking Ncf1 promotes
T-cell dependent autoimmune diseases [6]. Further, T-
cells activated by antigen presenting cells (APCs) induce
bone degradation in postmenopausal osteoporosis. After
ovariectomy (ovx), the excess tumor necrosis factor alpha
(TNFα) from T-cells activates OCL and results in reduced
bone density [7–9]. Other mechanisms underlying post-
menopausal bone loss include increased receptor activator
of nuclear factor κ B ligand (RANKL) signaling [10] and
increased OCL formation [11].
To investigate the role of ROS and Ncf1 in postmeno-
pausal bone loss, we employed a postmenopausal bone-
loss model by ovx or sham operating mice with a
spontaneous mutation in Ncf1. We investigated osteoclas-
togenesis ex vivo, used peripheral quantitative computed
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tomography (pQCT) for measuring bone mineral density
(BMD), and flow cytometry was used to investigate pre-
OCL and immune cells, including immune cell activa-
tion. We found that bone mineral density decreased to
the same extent in both Ncf1-deficient mice and wild
type (WT) mice, however, the OCL formation and pre-




The regional ethical review board in Gothenburg ap-
proved this study. The point mutation in Ncf1 [12] has
been backcrossed onto the B10Q background (WT) [6]
and kept in breeding. WT mice and mice derived from
the same background but with a homozygous mutation
in the Ncf1-gene (Ncf1*/*) were housed in a
temperature-controlled room with a 06.00–18.00 h light
cycle and consumed a soy-free diet (R70, Lantmännen,
Stockholm, Sweden) and tap water ad libitum.
Ovariectomy and treatment
At 7 to 10 weeks of age, female mice were ovariecto-
mized or sham-operated, under isoflurane (Baxter Med-
ical Ab, Kista, Sweden) anesthetization by inhalation.
Carprofen (Orion Pharma AB, Animal Health, Sollen-
tuna, Sweden) was administered subcutaneously as post-
operative analgesic.
Mice were implanted with slow release pellets contain-
ing placebo or 17β-Estradiol (E2) at the time of ovx
(0.05 mg E2/kg/day; 90-day release, Innovative Research
of America, Sarasota, FL). The animals were randomly
divided into 3 groups per genotype (6–9 mice per
group): sham + placebo, ovx + placebo or ovx + E2.
Treatment continued until study termination (4 weeks).
Tissue collection
Mice were terminated 4 weeks after ovx or sham opera-
tions. At the time of termination, mice were anesthetized
with ketamine (Pfizer AB, Täby, Sweden) and medetomi-
dine (Orion Pharma AB), bled and killed by cervical dis-
location. Mice body weights were recorded (WT sham
25 ± 3.2 g, WT Ovx 25 ± 3.0 g, Ncf1*/* Sham 25 ± 1.7 g,
Ncf1*/* Ovx 25 ± 1.5 g), uteri were weighed and one
femur was put in 4 % paraformaldehyde (PFA) for meas-
uring BMD. One femur and two tibiae (for osteoclast
differentiation) and one humerus (for FACS analysis)
were put in phosphate buffered saline (PBS).
Osteoclast differentiation
Bone-marrow derived macrophages (BMM) were cul-
tured and stimulated with macrophage colony stimulat-
ing factor (M-CSF) and RANKL to induce osteoclast
differentiation [13]. Bone marrow was flushed with
minimum essential medium Eagle’s alpha modification
(αMEM; Gibco, Grand Island, NY, USA) supplemented
with 10 % heat-inactivated fetal bovine serum (FBS;
Sigma-Aldrich®, St Louis, USA). Cells were incubated for
2 days at 37 °C in a humidified CO2 chamber on a cul-
ture dish (Corning®, Hickory, NC, USA) with αMEM-
medium containing 30 ng/ml M-CSF (R&D system Eur-
ope LTD, Abingdon, UK). After two days, the adhering
cells (BMMs) were detached, after which 5000 cells in
5 μl αMEM/10 % FBS were seeded at the center of 96-
well plates and left to adhere for 10 min. Subsequently,
200 μl medium was added containing either 30 ng/ml of
M-CSF (controls), or 30 ng/ml M-CSF + 2 ng/ml of
RANKL. After 4 days, the cells were fixed and stained
for tartrate-resistant acid phosphatase (TRAP). TRAP-
positive cells with ≥3 nuclei were considered osteoclasts.
The amounts of TRAP-positive multinucleated osteo-
clasts were calculated by standardized counting of the
midsection of a 96-well by Osteomeasure 3.2.1.0 soft-
ware (Osteometrics, Inc., Decatur, GA, USA) [14]. The
total OCL covered area in the well was calculated by tra-
cing the OCL boundaries. Area per individual OCL was
calculated by dividing OCL covered area with number of
OCL. Three mice per group were used and assayed in
quadruplicate.
Assessing BMD
After being kept for 2 days in 4 % PFA and subsequently
stored in 70 % ethanol, femurs were scanned using per-
ipheral quantitative computed tomography (pQCT) with
Stratec pQCT XCT Research M software (version 5.4B;
Norland, Fort Atkinson, WI, USA), at a resolution of
70 μm, as described previously [15]. Cortical thickness
was determined by one mid-diaphyseal scan at a dis-
tance from the distal growth plate corresponding to
36 % of total femur length. This mid-diaphyseal region
of mouse femur only contains cortical bone. Trabecular
BMD was determined by one metaphyseal scan at a dis-
tance from the distal growth plate corresponding to 3 %
of the femur length. The trabecular bone region was set
as 45 % of the inner total cross-sectional area.
Single cell preparation and immunophenotyping by flow
cytometry
Single cell suspensions for flow cytometry were prepared
from bone marrow as previously described [16]. Erythro-
cytes were lysed using Tris-buffered 0.83 % NH4Cl. Cells
were then stained with fluorochrome-conjugated anti-
bodies to detect different cell populations (Table 1).
Fluorescence-minus-one stained samples were used as
controls. Data was acquired on a BD FACS Canto II and
analyzed using Flow Jo 8.8.6 (Three Star Inc, Ashland,
USA). Macrophages were defined as CD11b+ M-CSFR+
cells; and pre-osteoclasts defined as CD11b+M-CSFR
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+RANK+ cells. Median Fluorescence Intensity, MFI,
was calculated of RANK expression on CD11b+M-
CSFR+ cells.
Estimation of ROS production
Dihydrorhodamine (DHR) 123 dye was used as a free
radical sensor (final concentration of 0.25 μg/ml, Life
Technologies, Carlsbad, CA, USA), which forms the
fluorescent product rhodamine 123 after oxidation.
To quantify the respiratory burst activity, bone mar-
row cells were incubated at 37 °C for 15 min with
phorbol myristate acetate (PMA, 0.5 μg/ml; Sigma-
Aldrich). Cells were washed with cold PBS, acquired
by a BD FACS Canto II (BD Biosciences, San Jose,
CA, USA), and analyzed using Flow Jo software
(FlowJo, LLC, Ashland, OR, USA).
Statistical analysis
Statistical evaluations were performed using IBM
SPSS Statistics for Macintosh, Version 22.0.0.0, re-
leased 2013 (IBM Corp, Armonk, NY, USA). As
bone mineral density measurements are sensitive to
sibling controls, statistical analysis was only used to
compare mice of the same genotypes. Student’s t-
test was used for comparison of two groups. When-
ever Levene’s test revealed unequal variances be-
tween the groups, Welch’s t-test was used instead.
Logarithmic transformations were used when appro-
priate to ensure normal distribution of data. P
values <0.05 were considered statistically significant.
GraphPad Prism version 6.0c was used for graphical
representations. Reported values are mean ± SD un-
less otherwise stated.
Results
Osteoclastogenesis increases after ovx in WT mice but
not in Ncf1*/*-mice
Osteoclastogenesis was induced from bone marrow cells.
We found an increase in the number of OCL formed ex
vivo after ovx in WT mice (Fig. 1a). However, in the
Ncf1*/*-mice, the number of OCL formed did not in-
crease after ovx (Fig. 1a). The total OCL area did not differ
between the groups (Fig. 1b). We confirmed the reduced
estrogen levels after ovx in both genotypes by measuring
uteri weights (WT sham 77 ± 41 mg, WT ovx 12 ± 1.6 mg,
p < 0.0001; Ncf1*/*- Sham 95 ± 30 mg, Ncf1*/*- ovx 13 ±
4.1 mg, p < 0.0001). We further confirmed that monocyte/
macrophages from WT mice produced more ROS than
Ncf1*/*-mice (Geometric mean fluorescence intensity
(gMFI): WT sham 542 ± 70, Ncf1*/* Sham 283 ± 89).
Ncf1 does not regulate ovx-induced bone loss
We measured BMD 4 weeks after ovx in both WT and
Ncf1*/*-mice. pQCT measurements revealed equally re-
duced trabecular BMD after ovx in WT and Ncf1*/
*-mice (Fig. 2a). Cortical thickness had decreased signifi-
cantly in the WT mice after ovx, but only borderline in
the Ncf1*/*-mice (Fig. 2b). To investigate a possible rate-
dependency of bone degradation after ovx, we also ana-
lyzed BMD 2 weeks after ovx in both genotypes. Tra-
becular BMD had decreased significantly in both
genotypes, whereas cortical thickness had not decreased
in either genotype at this earlier time point (data not
shown). We further investigated whether both genotypes
responded to E2 treatment after ovx-induced bone deg-
radation. We found that after 4 weeks of treatment, tra-
becular BMD (WT-E2 692 ± 73 mg/cm3, Ncf1*/*-E2 625
± 116 mg/cm3) and cortical thickness (WT-E2 0.23 ±
Table 1 Antibody table
Peptide/protein
target
Name of Antibody Manufacturer, catalog #, and/or name of individual
providing the antibody




M-CSFR APC anti-mouse CD115
(CSF-1R)
Biolegend, #135510 Rat, monoclonal 1:10
CD11b V450 anti-mouse CD11b BD Biosciences, #560455 Rat, monoclonal 1:50
CD8 PE anti-mouse CD8 BD Biosciences, #553033 Rat, monoclonal 1:50
CD8 PerCp anti-mouse CD8 BD Biosciences, #553036 Rat, monoclonal 1:50
CD4 V450 anti-mouse CD4 BD Biosciences, #560468 Rat, monoclonal 1:50
CD69 PE anti-mouse CD69 BD Biosciences, #561932 Armenian Hamster,
monoclonal
1:30
CD11c APC anti-mouse CD11c BD Biosciences, #550261 Armenian Hamster,
monoclonal
1:50
MHC II PerCp anti-mouse I - A/I-E
(MHC II)
Biolegend, #107624 Rat, monoclonal 1:50
CD80 Pacific Blue anti-mouse
CD80
Biolegend, #104724 Armenian Hamster, polyclonal 1:10
RANK PE anti-mouse CD265
(RANK)
Biolegend, #119806 Rat, monoclonal 1:20
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0.01 mm, Ncf1*/*-E2 0.23 ± 0.03 mm) increased in both
WT and Ncf1*/*-mice with this dose of E2. We also con-
firmed uteri growth after E2 treatment in both WT and
Ncf1*/*-mice (WT-E2 208 ± 46 mg, Ncf1*/*- E2 185 ±
60 mg).
RANK-expressing pre-OCL increase after ovx in Ncf1*/
*-mice
The two factors M-CSF and RANKL are important in
the formation of OCL [17]. The cytokine M-CSF
influences hematopoietic stem cells in the bone marrow
to differentiate into the family of macrophages. OCLs
forms from this M-CSF-dependent precursor, shared
with macrophages. When OCL precursors are incubated
with RANKL, these cells can further differentiate
through the RANK receptor and fuse into multinucle-
ated OCL. To evaluate the importance of Ncf1 in the for-
mation of macrophages and pre-osteoclasts, we analyzed
cells from the bone marrow using flow cytometry. The
frequency of macrophages expressing the M-CSF receptor
Fig. 1 Ovx of WT mice induces osteoclast formation, but not ovx of Ncf1*/*-mice. Number a and area b of OCL formed ex vivo in wild-type (WT)
and Ncf1-deficient (Ncf1*/*) mice after ovx or sham operations. In C-F, representative images of OCL are shown from the respective groups. Three
mice per group were used and assayed in quadruplicate. Data displays mean ± SD, *p < 0.05 in sham versus ovx mice
Fig. 2 BMD decreases in both WT and Ncf1*/*-mice after ovx. Mice were either ovx- or sham-operated for 4 weeks. Trabecular bone mineral dens-
ity and cortical thickness were evaluated by pQCT a-b. Data displays mean ± SD, *p < 0.05, ***p < 0.001 in sham versus ovx mice
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did not differ in either genotype (Fig. 3a). Neither did the
frequency of cells expressing F4/80 (results not shown).
However, the population of pre-osteoclastic macrophages
expressing RANK expanded in Ncf1*/*-mice after ovx, but
not in WT mice (Fig. 3b). There was no difference in MFI
expression of RANK (Fig. 3d).
Ovx leads to lymphocyte activation in both genotypes
According to previous studies, lymphocytes are involved
in the activation of OCL after ovx [7]. Ovx triggers
APCs to activate T-cells in order to stimulate OCL activ-
ity. Neither the general dendritic cell (DC) population
(CD11c+ cells) nor the MHC class II+DCs were affected
in either genotype 2 or 4 weeks after ovx (Table 2). The
CD80+DCs expanded in the Ncf1*/*-mice 4 weeks after
ovx (Table 2). The general CD4+ T-cell population de-
creased after ovx (Table 2), whereas the CD69+CD4+
cells increased in both genotypes 2 weeks after ovx
(Table 2). Similar results were found for the CD69+CD8+
cell population (Table 2).
Discussion
Bone resorption and bone formation shifts with advan-
cing age, leading to loss of bone mass and strength. In
postmenopausal women, both age and loss of estrogens
contribute to activating osteoclasts, inflammatory cells,
and induce ROS production in the bone marrow. In our
study, we found that ovx increases OCL formation ex
vivo in WT mice, accompanied by reduced cortical
thickness and trabecular BMD. In Ncf1*/* mice, no in-
crease in OCL formation was seen after ovx, indicating
that the Ncf1*/* should retain bone density after ovx.
Surprisingly, the Ncf1*/* mice loose BMD similar to WT
mice after ovx.
We investigated several possible mechanisms for this
found discrepancy. First, we investigated whether the
difference was present already on pre-OCL in the bone
marrow (defined as CD11b+M-CSFR+RANK+ macro-
phages) destined to become OCL upon stimulation. The
crucial role of Ncf1 for macrophage activation was previ-
ously shown where Ncf1 deleted specifically in macro-
phages regulated chronic inflammation [18–20]. In our
study, Ncf1*/* mice showed an expanded population of
pre-osteoclastic macrophages expressing RANK after
ovx (Fig. 3b), indicating that they are target cells also in
this model. One compensatory mechanism could be to
increase OCL sensitivity and upregulate RANK. We
could however not find any differences in the intensity
of RANK expression using FACS (Fig. 3d). In addition,
Ncf1*/* did not affect OCL area. This suggests that the
OCL retain their efficiency regardless of numbers, and
implies that it is the total bone area covered by the OCL
that is important. Previous studies have implicated that
NOX 1, 2 and 4 are important in bone loss. The OCL
has been shown to switch NOX-complex in order to
produce the necessary levels of ROS, possibly as a com-
pensatory mechanism to ensure an adequate bone re-
sorption process [21]. NOX 4 was shown to be more
active in bone resorption in young mice [22], whereas
the NOX 2 complex was shown to be important for
bone loss in elderly mice (more than 2 years of age [23].
Those studies verified the importance of the two NOX
complexes for bone resorption at different ages, and sug-
gest that NOX 4 may compensate for lost ROS produc-
tion in Ncf1*/* mice.
The bone remodeling process was comparably regu-
lated by estrogen treatment in this study, as treating ovx
mice with E2 resulted in similar increases in cortical
thickness and trabecular BMD in both Ncf1*/* and WT-
mice. However, interactions between E2 and Ncf1 were
possibly concealed in this study due to the high dose
and duration of the estrogen treatment.
Fig. 3 Pre-osteoclasts expand in Ncf1*/*-mice after ovx. Bone marrow cells were evaluated using FACS. Populations of macrophages (% CD11b+
M-CSFR+ cells; a, or pre-osteoclasts (% CD11b+M-CFSR+ RANK+ cells; b were evaluated after ovx in WT or Ncf1*/* mice. A representative FACS-plot
of RANK expression on CD11b+M-CSFR+ cells is displayed in c, and Median Fluorescent Intensity, MFI expression for RANK on CD11b+M-CFSR+
cells is presented in d. Data displays mean ± SD, *p < 0.05 in sham versus ovx mice
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In previous studies of postmenopausal bone loss, acti-
vated Tcells and APCs were shown to regulate the bone re-
sorption process [7]. Since Ncf1 regulates auto-reactive T
cells through APCs in autoimmunity, we further investi-
gated activated T cells and DCs. We found similar changes
at 2 weeks in both WT and Ncf1*/* mice, whereas at 4
weeks after ovx, the CD80+DCs population was expanded
in the Ncf1*/*-mice. This indicates a possible rate differ-
ence, and that a target mechanism lies further up in the
hierarchy, such as on the pre-OCL or macropages, or on
soluble factors secreted from the activated APCs. TNFα is
produced in abundance after ovx, and can induce osteoclas-
togenesis by itself. A possible discrepancy between OCL
formation after stimulation with RANKL, TNFα and other
cytokines in the Ncf1*/*-mice will be subject for further
studies. Both the increased RANK- expression on macro-
phages and lingering increased CD80+DCs in Ncf1*/*-mice
could contribute to an altered bone degradation process,
such as we discerned of the cortical bone in Ncf1*/*-mice.
The lack of statistically significant difference in cortical
thickness of Ncf1*/*-mice could either be due to a too small
number of animals used in each group, or it is possible that
other more sensitive BMD measurement techniques such
as microCT could detect finer details and differences in the
rate dependent bone degradation processes, thus revealing
additional aspects regarding effects of Ncf1 on bone. The
model we used in this study is a global Ncf1-deficiency
model, reducing Ncf1 function in all cells. Therefore, pos-
sible mechanisms regulated by Ncf1 includes effects on os-
teoblasts, altered regulation of the cross-talk between
osteoblasts and OCL, compensatory ROS production from
another NOX or regulating another mechanism altogether,
all of which are subjects for future studies.
Conclusion
Here, using a model of postmenopausal bone loss, we
report that Ncf1, an essential subunit of the ROS-
producing NOX 2 complex, contributes to OCL forma-
tion possibly by regulating pre-OCL. The NOX com-
plexes are active in many physiological and
pathophysiological processes. Increasing our understand-
ing of their function will help in producing new targets
for alleviating disease.
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